Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Instruments - Additional Information (Details)

Fair Value of Financial Instruments - Additional Information (Details) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 01, 2021 USD ($) Milestonepayment	Mar. 31, 2022 USD ($)	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments		$ 1,200
Discount Rate
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-adjusted discount rate			0.3500
Contingent Consideration, Second Component \| Alkermes Plc \| Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval \| Amendment to Purchase and Sale Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| Milestonepayment	7
Business acquisition, contingent consideration, equal annual milestone payments	$ 6,400
Contingent Consideration, Fourth Component \| Alkermes Plc \| Amendment to Purchase and Sale Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum royalty payment percentage			30.00%
Contingent Consideration, Fourth Component \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Royalty payment percentage			10.00%
Contingent Consideration, Fourth Component \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Royalty payment percentage			12.00%